捷捷微電(300623.SZ):是集芯片研發、芯片製造、封測和銷售為一體的江蘇省高新技術企業
格隆匯7月1日丨捷捷微電(300623.SZ)在投資者互動平台表示,公司是集芯片研發、芯片製造、封測和銷售為一體的江蘇省高新技術企業。主導產品為單、雙向可控硅、MOSFET (SGT、溝槽、平面、超結等工藝)、低結電容 ESD、TVS、低結電容放電管等各類保護器件、高壓整流二極管、功率型開關晶體管。公司下游客户眾多並分散,且應用領域廣泛。按照產品的應用領域的不同,大致分為這幾個類別:白色家電、小家電、漏保、電力電子模塊、照明、安防、通訊、電錶、汽車電子、光伏、電動工具和摩配等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.